4QK Stock Chart & Stats
€1.40
<€0.01(0.46%)
At close: 4:00 PM EDT
€1.40
<€0.01(0.46%)
Day’s Range― - ―
52-Week Range€0.83 - €2.45
Previous CloseN/A
Volume0.00
Average Volume (3M)13.00
Market Cap
€126.90M
Enterprise Value€223.03
Total Cash (Recent Filing)€54.92M
Total Debt (Recent Filing)€72.59M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Oct 29, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding109,505,770
10 Day Avg. Volume10
30 Day Avg. Volume13
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.81
Price to Sales (P/S)2.02
P/FCF Ratio-5.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.71Price Target Upside307.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.32
Revenue Forecast (FY)€64.63M
Bulls Say, Bears Say
Bulls Say
High Margins And Cost DisciplineThe 73% product gross margin indicates strong potential economics for Codexis’s enzyme solutions, while lower R&D and SG&A show improving expense discipline. Together, these trends can support better operating leverage if revenue recovers and commercial activity scales.
Commercial Pipeline DepthA broad base of commercial products and late-stage partner programs gives Codexis multiple avenues for recurring enzyme demand and milestone-related activity. This diversified pipeline can create durable growth opportunities beyond any single customer, product, or development outcome.
Extended Liquidity RunwayThe strengthened cash position gives Codexis time to fund operations, planned capital spending, and ECOsynthesis development without an immediate need for additional financing. A runway through 2028 improves execution flexibility while commercial programs mature and scale.
Bears Say
Severe Revenue And Profitability PressureThe sharp TTM revenue contraction and deeply negative operating and net margins show that Codexis has not yet converted its technology and customer activity into sustainable profitability. Continued losses make future growth dependent on stronger commercial traction and improved operating leverage.
Negative Cash GenerationPersistent operating and free-cash-flow deficits mean Codexis is not currently self-funding its business or development plans. Even with an improved burn rate, ongoing cash consumption can constrain investment choices and increase reliance on external capital if operating progress falls short.
ECOsynthesis Scale-up And Conversion RiskECOsynthesis offers meaningful strategic potential, but its key capabilities remain short of demonstrated commercial scale. Technical hurdles and the need to reach kilogram production create execution risk, while delayed industrialization could postpone customer adoption, contracts, and related revenue.
Codexis News
4QK FAQ
What was Codexis’s price range in the past 12 months?
Codexis lowest stock price was €0.83 and its highest was €2.45 in the past 12 months.
What is Codexis’s market cap?
Codexis’s market cap is €126.90M.
When is Codexis’s upcoming earnings report date?
Codexis’s upcoming earnings report date is Oct 29, 2026 which is in 31 days.
How were Codexis’s earnings last quarter?
Codexis released its earnings results on Aug 11, 2026. The company reported -€0.113 earnings per share for the quarter, beating the consensus estimate of -€0.124 by €0.01.
Is Codexis overvalued?
According to Wall Street analysts Codexis’s price is currently Undervalued.
Does Codexis pay dividends?
Codexis does not currently pay dividends.
What is Codexis’s EPS estimate?
Codexis’s EPS estimate is -0.08.
How many shares outstanding does Codexis have?
Codexis has 109,505,770 shares outstanding.
What happened to Codexis’s price movement after its last earnings report?
Codexis reported an EPS of -€0.113 in its last earnings report, beating expectations of -€0.124. Following the earnings report the stock price went up 8.333%.
Which hedge fund is a major shareholder of Codexis?
Currently, no hedge funds are holding shares in DE:4QK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Codexis Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.71 (307.60% Upside)
€5.71 (307.60% Upside)
Blogger Sentiment
Bearish
DE:4QK Sentiment 100%
Sector Average 64%
Sector Average 64%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-13.16%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Codexis
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
4QK Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive strategic and technical narrative: clear technology milestones (stereochemistry control, Starterless initiation), progressing scale demonstrations (hundreds of grams toward kilogram scale), active CDMO and biopharma engagements, improving product gross margin (73%) and disciplined expense reductions. Financially, the company showed a modest year-over-year revenue decline in the quarter, a pre-financing drop in cash balance, and an ongoing net loss. These negatives are mitigated by a successful $25M financing that restores pro forma cash to ~$79.8M and management's stated cash runway through 2028, plus reiterated 2026 revenue guidance ($70M–$76M). The primary remaining risks are revenue lumpiness, the need to convert pilot/tech-transfer activity into firm commercial contracts, and successfully industrializing ECOsynthesis at commercial scale. On balance, highlights (technical differentiation, commercial engagement, margin improvement, financing and runway) outweigh the lowlights (quarterly revenue decline, cash drawdown prior to financing, execution risk), supporting a constructive view of progress and prospects.View all DE:4QK earnings summaries4QK Stock 12 Month Forecast
Average Price Target
€5.71
▲(307.60% Upside)
Technical Analysis
Cartesian Therapeutics
―
Cabaletta Bio
―
Elicio Therapeutics
―
Vor Biopharma
―
OmniAb
―